Golodirsen for Duchenne muscular dystrophy.

Abstract

Duchenne muscular dystrophy (DMD) is a life-shortening X-linked genetic disorder characterized by progressive wasting and weakening of muscles in boys. Loss-of-function mutations in the DMD gene, which codes for dystrophin, lead to this disease. The majority of mutations in this gene result in the exclusion of one or more exons from the transcript, eventually causing the remaining exons not to fit together correctly (i.e., out-of-frame mutations). Antisense oligonucleotides, e.g., phosphorodiamidate morpholino oligomers (PMOs), can induce therapeutic exon skipping during pre-mRNA processing to restore the reading frame of the primary transcript of DMD. As a result, truncated but partially functional dystrophin is produced, potentially slowing down the disease progression. Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping. This article summarizes golodirsen's pharmacology, efficacy and safety information. It also discusses some controversies that golodirsen met after the approval.

• Authors: S Anwar, T Yokota
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 56 Issue 8 Pg. 491-504 (Aug 2020) ISSN: 1699-3993 [Print] Spain
• PMID: 33025945 (Publication Type: Journal Article)
• Copyright: Copyright 2020 Clarivate Analytics.

Chemical References

• Dystrophin
• Morpholinos
• Oligonucleotides
• Oligonucleotides, Antisense
• golodirsen

Topics

• Dystrophin
• Exons
• Humans
• Morpholinos (therapeutic use)
• Muscular Dystrophy, Duchenne (drug therapy)
• Oligonucleotides (therapeutic use)
• Oligonucleotides, Antisense (therapeutic use)